Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture

Cited by (1,000)

Items 601–700 of 1,000

1. Effect of alendronate in elderly patients after low trauma hip fracture repair
   D. Cecilia-López, Esteban Jódar, Cristina Fernández, C. Resines, Federico Gustavo Hawkins · 2008 · Osteoporosis International
2. Long Term Bisphosphonate Use in Osteoporotic Patients; A Step Forward, Two Steps Back
   Pooneh Salari, Mohammad Reza Abdollahi · 2012 · Journal of Pharmacy & Pharmaceutical Sciences
3. Implications of expanding indications for drug treatment to prevent fracture in older men in United States: cross sectional and longitudinal analysis of prospective cohort study
   Kristine E. Ensrud, Brent C Taylor, K. W. Peters, M. L. Gourlay, Meghan G Donaldson, William Donald Leslie, TERRI L. BLACKWELL, Howard A Fink, ERIC S. ORWOLL, John T. Schousboe et al. · 2014 · BMJ
4. Current options for the management of postmenopausal osteoporosis
   Marie-Paule Lecart, Jean‐Yves Reginster · 2011 · Expert Opinion on Pharmacotherapy
5. Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment
   Serge Ferrari, Peter W Butler, David L. Kendler, Paul D. Miller, Christian Roux, Andrea T Wang, Shuang Huang, Rachel B. Wagman, Edward Michael Lewiecki · 2019 · The Journal of Clinical Endocrinology & Metabolism
6. Drug Insight: choosing a drug treatment strategy for women with osteoporosis—an evidence-based clinical perspective
   Piet Geusens, Christian Roux, David M. Reid, Willem Frederik Lems, Silvano Adami, Jonathan Derrick Adachi, Philip N. Sambrook, Kenneth G. Saag, Nancy E. Lane, Marc C. Hochberg · 2008 · Nature Clinical Practice Rheumatology
7. Favorable skeletal benefit/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed
   Serge Ferrari, Edward Michael Lewiecki, Peter W Butler, David L. Kendler, Nicola Napoli, Shuang Huang, Daria B. Crittenden, Nicola Pannacciulli, Ethel S. Siris, Neil Binkley · 2020 · Bone
8. The treatment gap after major osteoporotic fractures in Denmark 2005-2014: a combined analysis including both prescription-based and hospital-administered anti-osteoporosis medications
   Michael Kriegbaum Skjødt, M. T. Ernst, Sara Khalid, Cesar R. Libanati, Cyrus C. Cooper, Antonella Delmestri, Katrine Hass Rubin, M K Javaid, Daniel Martínez-Laguna, Ervin Tóth et al. · 2021 · Osteoporosis International
9. Clinical Efficacy and Safety of Zoledronic Acid Combined with PVP/PKP in the Treatment of Osteoporotic Vertebral Compression Fracture: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
   Yan Sun, Haoning Ma, Feng Yang, Xiangsheng Tang, Ping Yi, Mingsheng Tan · 2021 · BioMed Research International
10. Zoledronic acid and atrial fibrillation in cancer patients
    Çağatay Arslan, Sercan Aksoy, Ömer Dızdar, Didem Şener Dede, Hakan Harputluoğlu, Kadri Altundağ · 2010 · Supportive Care in Cancer
11. Long-term risks of bisphosphonate therapy
    Nelson B. Watts · 2014 · Arquivos Brasileiros de Endocrinologia & Metabologia
12. Hip Fractures
    John Edward Morley · 2010 · Journal of the American Medical Directors Association
13. Denosumab: A cost-effective alternative for older men with osteoporosis from a Swedish payer perspective
    Anju Parthan, M. Kruse, Irene Agodoa, Stuart L. Silverman, ERIC S. ORWOLL · 2013 · Bone
14. Caring for people with dementia
    MURNA G. DOWNS, Barbara J. Bowers · 2008 · BMJ
15. A New Index Based on Serum Creatinine and Cystatin C Can Predict the Risks of Sarcopenia, Falls and Fractures in Old Patients with Low Bone Mineral Density
    Jiaying Ge, Jiangping Zeng, Huihui Ma, Siqi Sun, Zheng Zhao, Yujie Jing, Chunhua Qian, Zhaoliang Fei, Ran Cui, Shen Qu et al. · 2022 · Nutrients
16. Current and future treatments of osteoporosis in men
    Jean‐Marc Kaufman, Bruno Lapauw, Stefan Goemaere · 2014 · Best Practice & Research Clinical Endocrinology & Metabolism
17. Management of fracture risk in Parkinson's: A revised algorithm and focused review of treatments
    Emily J. Henderson, Veronica Lyell, Arti Gauvri Bhimjiyani, Jigisha Amin, Christopher Kobylecki, Celia Louise Gregson · 2019 · Parkinsonism & Related Disorders
18. Treatment of osteoporosis after hip fracture is associated with lower all-cause mortality: A nationwide population study
    Ta‐Wei Tai, Chia‐Chun Li, Chun‐Feng Huang, Wing Pong Chan, Chih‐Hsing Wu · 2021 · Bone
19. Use of Bisphosphonates in Orthopedic Surgery
    Santiago A. Lozano‐Calderón, Matthew W. Colman, Kevin A. Raskin, Francis John Hornicek, Mark C. Gebhardt · 2014 · Orthopedic Clinics of North America
20. Secondary Prevention After an Osteoporosis-Related Fracture
    Joanna E. M. Sale, Dorcas Beaton, Earl R. Bogoch · 2014 · Clinics in Geriatric Medicine
21. Bone Density Screening and Re-screening in Postmenopausal Women and Older Men
    Margaret L. Gourlay, Robert A. Overman, Kristine E. Ensrud · 2015 · Current Osteoporosis Reports
22. Fracture Liaison Services: Promoting Enhanced Bone Health Care
    Juliet Aizer, Marcy B. Bolster · 2014 · Current Rheumatology Reports
23. Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta
    Jeffrey A. Meganck, Dana L. Begun, John-David P. McElderry, A. Swick, Kenneth M. Kozloff, Steven A. Goldstein, M. D. Morris, Joan C. Marini, Michelle S. Caird · 2013 · Bone
24. Bisphosphonate safety and efficacy in chronic kidney disease
    Susan M. Ott · 2012 · Kidney International
25. Alendronate and Raloxifene Use Related to Cardiovascular Diseases: Differentiation by Different Dosing Regimens of Alendronate
    Pei-Yu Lu, Chi-Feng Hsieh, Yi‐Wen Tsai, Weng-Foung Huang · 2011 · Clinical Therapeutics
26. Osteoporosis Update From the 2010 Santa Fe Bone Symposium
    Edward Michael Lewiecki, John Paul Bilezikian, Sundeep Khosla, Robert Marcus, Michael R. McClung, Paul D. Miller, Nelson B. Watts, Michael J. Maricic · 2011 · Journal of Clinical Densitometry
27. Results of a fracture liaison service on hip fracture patients in an open healthcare system
    Felicia Cosman, Kathleen Nicpon, Jeri Wanzor Nieves · 2016 · Aging Clinical and Experimental Research
28. Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies
    David A. Hanley, Michael R. McClung, Kenneth Shawn Davison, Larry Dian, Steve T. Harris, Paul D. Miller, Edward Michael Lewiecki, David L. Kendler · 2017 · The American Journal of Medicine
29. Fracture liaison services: do they reduce fracture rates?
    Irma J. A. de Bruin, Caroline E. Wyers, Joop P. van den Bergh, Piet Geusens · 2017 · Therapeutic Advances in Musculoskeletal Disease
30. Therapeutic strategy for atherosclerosis based on bone-vascular axis hypothesis
    Jeong‐Min Kim, Wang Soo Lee, Jaetaek Kim · 2019 · Pharmacology & Therapeutics
31. Osteoporosis: from a rare symptom of endocrine diseases to the tacit epidemic of XX-XXI centuries
    Ivan Ivanovich Dedov, Galina Afanas'evna Mel'nichenko, Ж. Е. Белая, Л. Я. Рожинская · 2011 · Problems of Endocrinology
32. Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years
    Ian R. Reid, Anne M. Horne, Borislav Mihov, Usha Bava, Angela Stewart, Greg D. Gamble · 2024 · The Lancet Diabetes & Endocrinology
33. Osteoporose – Definition, Risikoerfassung, Diagnose, Prävention und Therapie (Update 2024)
    Hans Peter Dimai, Christian Muschitz, Karin Amrein, Rosemarie Bauer, Daniel Cejka, Rudolf Wolfgang Gasser, Reinhard Gruber, Judith Haschka, Timothy Hasenoehrl, Franz M. Kainberger et al. · 2024 · Wiener klinische Wochenschrift
34. Established and forthcoming drugs for the treatment of osteoporosis
    Willem Frederik Lems, Piet Geusens · 2014 · Current Opinion in Rheumatology
35. Advanced Age, High β-CTX Levels, and Impaired Renal Function are Independent Risk Factors for All-Cause One-Year Mortality in Hip Fracture Patients
    Tonko Gulin, Ivan Kruljac, Lora Stanka Kirigin, Marcela Merc, Marina Pavić, Mirna Tominac Trcin, Adrijana Bokulić, Željka Bukovec Megla, Darko Kaštelan · 2015 · Calcified Tissue International
36. Comparative Efficacy of Bisphosphonates to Prevent Fracture in Men with Osteoporosis: A Systematic Review with Network Meta-Analyses
    Junwen Zhou, Tiansheng Wang, Xilan Zhao, Donald R. Miller, Suodi Zhai · 2016 · Rheumatology and Therapy
37. Frequency of normal bone measurement in postmenopausal women with fracture: a registry-based cohort study
    Neil Binkley, Suzanne N. Morin, Patrick Martineau, Lisa Marie Lix, Didier B. Hans, William Donald Leslie · 2020 · Osteoporosis International
38. Recommendations by the Spanish Society of Rheumatology on Osteoporosis
    Antonio Naranjo, Petra Díaz del Campo Fontecha, María Pilar Aguado Acín, Luis Marcelino Arboleya Rodríguez, E. Casado, Santos Castañeda, Jordi Fiter Aresté, Laia Gifre, Carmen Gómez Vaquero, Gloria Candelas Rodríguez et al. · 2019 · Reumatología Clínica (English Edition)
39. Cardiovascular Safety and Effectiveness of Bisphosphonates: From Intervention Trials to Real-Life Data
    Chiara Delli Poggi, Maria Fusaro, Maria Cristina Mereu, Maria Luisa Brandi, Luisella Cianferotti · 2022 · Nutrients
40. Post-surgery interventions for hip fracture: a systematic review of randomized controlled trials
    Jie Kie Phang, Zhui Ying Lim, Wan Qi Yee, Cheryl Yan Fang Tan, Yu Heng Kwan, Lian Leng Low · 2023 · BMC Musculoskeletal Disorders
41. Duration of Antiresorptive Effects of Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized, Placebo-Controlled Trial
    Andrew B. Grey, Mark J Bolland, Bobby Mihov, Sumwai Wong, Anne M. Horne, Greg D. Gamble, Ian R. Reid · 2013 · Journal of Bone and Mineral Research
42. Impact of Bisphosphonates on the Risk of Atrial Fibrillation
    Patricia A Howard, Brian J. Barnes, James L. Vacek, Warren Chen, Sue‐Min Lai · 2010 · American Journal of Cardiovascular Drugs
43. Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass
    Ronald C. Hamdy · 2010 · Drug Design Development and Therapy
44. Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass
    Peyman Hadji, D. Gamerdinger, W. Spieler, P. H. Kann, Helmut Loeffler, Konstantin Articus, Rüdiger Moericke, Volker Ziller · 2011 · Osteoporosis International
45. Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review
    Manju Mamtani, Hemant R. Kulkarni · 2009 · Osteoporosis International
46. Established Osteoporosis Associated with High Mortality after Adjustment for Age and Co-Mobidities in Postmenopausal Japanese Women
    Masataka Shiraki, Tatsuhiko Kuroda, Shiro Tanaka · 2011 · Internal Medicine
47. Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women
    Mickaël Hiligsmann, Olivier Bruyère, Jean‐Yves Reginster · 2009 · Osteoporosis International
48. Medical Treatment of Osteoporotic Vertebral Fractures
    Bente Lomholt Langdahl, Torben Harsløf · 2011 · Therapeutic Advances in Musculoskeletal Disease
49. Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained
    Richard Eastell, Dennis M. Black, Li‐Yung Lui, Arkadi A. Chines, Fernando Marín, Sundeep Khosla, Anne E. de Papp, Jane A. Cauley, Bruce Mitlak, Charles E. McCulloch et al. · 2020 · Journal of Bone and Mineral Research
50. Department of Veterans Affairs Geriatric Research, Education and Clinical Centers: Translating Aging Research into Clinical Geriatrics
    Mark A. Supiano, Cathy Alessi, Ronni Chernoff, Andrew Goldberg, John Edward Morley, Kenneth E. Schmader, Kenneth Shay · 2012 · Journal of the American Geriatrics Society
51. Calcium phosphate cement delivering zoledronate decreases bone turnover rate and restores bone architecture in ovariectomized rats
    Chang‐Chin Wu, Chen‐Chie Wang, Dai-Hua Lu, Li-Ho Hsu, Kai‐Chiang Yang, Feng‐Huei Lin · 2012 · Biomedical Materials
52. The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-α]Pyridin-3-yl)-Ethyl-Bisphosphonate)
    Michelle Anne Lawson, Frank H. Ebetino, Adam Mazur, Andrew Chantry, Julia Paton‐Hough, Holly Evans, Darren Lath, Maria K. Tsoumpra, Mark Walden Lundy, Roy L. M. Dobson et al. · 2017 · Journal of Bone and Mineral Research
53. Advances and Unmet Needs in the Therapeutics of Bone Fragility
    Sabashini K. Ramchand, Ego Seeman · 2018 · Frontiers in Endocrinology
54. Timing of anti-osteoporosis medications initiation after a hip fracture affects the risk of subsequent fracture: A nationwide cohort study
    Chen-Yu Wang, Shau‐Huai Fu, Rong‐Sen Yang, Liang‐Kung Chen, Li‐Jiuan Shen, Fei‐Yuan Hsiao · 2020 · Bone
55. Denosumab for cancer-related bone loss
    Emanuela Dell’Aquila, Grazia Armento, Michele Iuliani, Sonia Simonetti, Loretta D’Onofrio, Tea Zeppola, Cristina Madaudo, Marco Russano, Fabrizio Citarella, Giulia Ribelli et al. · 2020 · Expert Opinion on Biological Therapy
56. The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism
    Caroline M. Tanner, Steven Ron Cummings, Michael A. Schwarzschild, Ethan G. Brown, Earl Ray Dorsey, Alberto Javier Espay, Nicholas B. Galifianakis, Samuel M. Goldman, Irene Litvan, Nijee Luthra et al. · 2021 · npj Parkinson s Disease
57. Burden of osteoporosis in Vietnam: An analysis of population risk
    Duy K. Hoang, Minh C. Doan, Dao Nguyen Phuong Linh, Thao Phuong Ho-Le, Lan Thuc Ho-Pham · 2021 · PLoS ONE
58. Reduced All‐Cause Mortality With Bisphosphonates Among Post‐Fracture Osteoporosis Patients: A Nationwide Study and Systematic Review
    Yu‐Hsuan Hsu, Chia‐Chun Li, Fu‐Wen Liang, Zi‐Yang Peng, Yin‐Fan Chang, Jason C. Hsu, Huang‐Tz Ou, Chih‐Hsing Wu · 2022 · Clinical Pharmacology & Therapeutics
59. Gaps and alternative surgical and non-surgical approaches in the bone fragility management: an updated review
    Umberto Tarantino, Ida Cariati, Chiara Greggi, Riccardo Iundusi, Elena Gasbarra, Giovanni Iolascon, Andreas Kurth, Kristina Åkesson, Mary Bouxsein, Paolo Tranquilli Leali et al. · 2022 · Osteoporosis International
60. Fracture prevention in postmenopausal women.
    Leif Mosekilde, Peter Vestergaard, Bente Lomholdt Langdahl · 2006 · Europe PMC (PubMed Central)
61. Risk of mortality and predisposing factors after osteoporotic hip fracture: a one-year follow-up study
    Marta González-Rozas, José Luis Pérez‐Castrillón, Manuel Gonzalez Sagrado, Marta Ruiz‐Mambrilla, Manuel García-Alonso · 2012 · Aging Clinical and Experimental Research
62. Seizures Associated with Zoledronic Acid for Osteoporosis
    Elena A. Tsourdi, Tilman D. Rachner, Matthias Grüber, Christine Hamann, Tjalf Ziemssen, Lorenz Christian Hofbauer · 2011 · The Journal of Clinical Endocrinology & Metabolism
63. 2008 Santa Fe Bone Symposium: Update on Osteoporosis
    Edward Michael Lewiecki, Sanford Baim, John Paul Bilezikian, Richard Eastell, Meryl Susan LeBoff, Paul D. Miller · 2009 · Journal of Clinical Densitometry
64. Development of oral osteomucosal tissue constructs in vitro and localization of fluorescently-labeled bisphosphonates to hard and soft tissue
    Susan Bae, Shuting Sun, Tara L Aghaloo, Ju-Eun Oh, Charles E. McKenna, Mo Kang, KI-HYUK SHIN, Sotirios Tetradis, No‐Hee Park, Reuben H. Kim · 2014 · International Journal of Molecular Medicine
65. Intravenous bisphosphonate therapy and atrial fibrillation/flutter risk in cancer patients: a nationwide cohort study
    Rune Erichsen, Christian Fynbo Christiansen, Trine Frøslev, Jacob Bonde Jacobsen, Henrik Toft Sørensen · 2011 · British Journal of Cancer
66. Second hip fracture and patients’ medication after the first hip fracture: A follow-up of 221 hip fracture patients in Finland
    Juha-Pekka Kaukonen, Peter M.J. Lüthje, Ilona Nurmi-Lüthje, Matti Kataja, Helena Naboulsi · 2010 · Archives of Gerontology and Geriatrics
67. Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management
    Boon Hui Chan, Raymond K. Yee, Rukshini Puvanendran, Seng Bin Ang · 2018 · Singapore Medical Journal
68. Clinical practice guideline: The diagnosis and treatment of osteoporosis
    Friederike E Thomasius, Andreas Kurth, Erika Baum, Michael Drey, Uwe Martin Maus, Ralf Schmidmaier · 2025 · Deutsches Ärzteblatt international
69. Low prevalence of osteoporosis treatment in patients with recurrent major osteoporotic fracture
    Jérémy Flais, Guillaume Coiffier, José Le Noach, Jean-David Albert, Marine Faccin, Aleth Perdriger, Hervé Thomazeau, Pascal Guggenbuhl · 2017 · Archives of Osteoporosis
70. The burden of hip fractures—why aren’t we better at prevention?
    Ami Schattner · 2017 · QJM
71. Actualisation 2018 des recommandations françaises du traitement de l’ostéoporose post-ménopausique
    Karine Briot, Christian Roux, Thierry Thomas, Hubert Blain, Daniel Buchon, Roland D Chapurlat, Françoise Debiais, J.-M. Féron, Jean Bernard Gauvain, Pascal Guggenbuhl et al. · 2018 · Revue du Rhumatisme
72. Efficacy of non-steroidal anti-inflammatory drugs on zoledronic acid-induced acute-phase reactions: randomized, open-label, Japanese OZ study
    Nobukazu Okimoto, Akinori Sakai, Toru Yoshioka, Tomohiro Kobayashi, Kei Asano, Shojiro Akahoshi, Toru Ishikura, Shito Fukuhara, Yoshifumi Fuse, Toshiyuki Mizuno et al. · 2019 · Journal of Bone and Mineral Metabolism
73. Comparative effectiveness of denosumab, teriparatide, and zoledronic acid among frail older adults: a retrospective cohort study
    Andrew R. Zullo, Y. Lee, Christine W. Lary, Lori A. Daiello, Douglas P. Kiel, Sarah D. Berry · 2021 · Osteoporosis International
74. Mortality and Related Risk Factors of Fragile Hip Fracture
    Pei‐Wen Wang, Xuedong Yao, Huafeng Zhuang, Yizhong Li, Hao Ying Xu, Jinkuang Lin, Wen‐Ge Liu · 2022 · Orthopaedic Surgery
75. The impact of dietary calcium intake and vitamin D status on the effects of zoledronate
    S. Bourke, Mark J Bolland, Andrew B. Grey, Anne M. Horne, Diana J. Wattie, Stanford Chun Yin Wong, Greg D. Gamble, Ian R. Reid · 2012 · Osteoporosis International
76. Bisphosphonates and osteonecrosis of the jaw: Innocent association or significant risk?
    JOHN J. CAREY, Leena Palomo · 2008 · Cleveland Clinic Journal of Medicine
77. Osteoporosis Screening and Treatment Among Veterans with Recent Fracture After Implementation of an Electronic Consult Service
    Richard Lee, Kenneth W. Lyles, Megan Pearson, Karen Barnard, Cathleen S Colon-Emeric · 2014 · Calcified Tissue International
78. Bone-forming agents in the management of osteoporosis
    Audrey Neuprez, Jean‐Yves Reginster · 2008 · Best Practice & Research Clinical Endocrinology & Metabolism
79. Calcium Sulphate/Hydroxyapatite Carrier for Bone Formation in the Femoral Neck of Osteoporotic Rats
    Aurimas Širka, Deepak Bushan Raina, Hanna Isaksson, K.E. Tanner, Alfredas Smailys, Ashok Kumar, Šarūnas Tarasevičius, Magnus Tägil, Lars Lidgren · 2018 · Tissue Engineering Part A
80. Hip Fracture: A Complex Illness Among Complex Patients
    William W. Hung, R. Sean Morrison · 2011 · Annals of Internal Medicine
81. Calcium Abnormalities in Hospitalized Patients
    Sarah French, José S. Subauste, Stephen A. Geraci · 2012 · Southern Medical Journal
82. Diagnosis and treatment of Paget’s disease of bone
    Christian Muschitz, Xaver Feichtinger, Judith Haschka, Roland Kocijan · 2016 · Wiener Medizinische Wochenschrift
83. Risk of Incident Atrial Fibrillation With Zoledronic Acid Versus Denosumab: A Propensity Score–Matched Cohort Study
    Kristin M. D’Silva, SARA JANE CROMER, Elaine Wei-Yin Yu, Michael A. Fischer, Seoyoung C. Kim · 2020 · Journal of Bone and Mineral Research
84. Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study
    Masataka Shiraki, Tatsuhiko Kuroda, Yasuhiro Takeuchi, Toshitsugu Sugimoto, Satoshi Tanaka, Hiroaki Suzuki, Kazuki Hiraishi, Toshitaka Nakamura · 2021 · Calcified Tissue International
85. Guideline No. 422g: Menopause and Osteoporosis
    Aliya Aziz Khan, Hajar Abu Alrob, Dalal S. Ali, Karel Dandurand, Wendy Wolfman, Michel P. Fortier · 2022 · Journal of Obstetrics and Gynaecology Canada
86. Osteoporosis Medications Prevent Subsequent Fracture in Frail Older Adults
    Tanchanok Chattaris, Gahee Oh, Natalia Gouskova, Dae Hyun Kim, Douglas P. Kiel, Sarah D. Berry · 2020 · Journal of Bone and Mineral Research
87. Cardiac adverse events in bisphosphonate and teriparatide users: An international pharmacovigilance study
    Alexander J. Rodríguez, Nitesh Nerlekar, Peter Robert Ebeling · 2022 · Bone
88. A summary of the Russian clinical guidelines on the diagnosis and treatment of osteoporosis
    Zhanna E. Belaya, Liudmila Y. Rozhinskaya, Ivan Ivanovich Dedov, Oksana M. Drapkina, Valentin V. Fadeev, Olga O. Golounina, O. M. Lesnyak, Elizaveta Mamedova, Galina Afanas'evna Mel'nichenko, Alexey Vladimirovich Petraikin et al. · 2023 · Osteoporosis International
89. Summary of the Thai Osteoporosis Foundation (TOPF) Clinical Practice Guideline on the diagnosis and management of osteoporosis 2021
    Natthinee Charatcharoenwitthaya, Unnop Jaisamrarn, Thawee Songpatanasilp, Vilai Kuptniratsaikul, Aasis Unnanuntana, Chanika Sritara, Hataikarn Nimitphong, Lalita Wattanachanya, Pojchong Chotiyarnwong, Tanawat Amphansap et al. · 2023 · Osteoporosis and Sarcopenia
90. Pre-treatment bone mineral density and the benefit of pharmacologic treatment on fracture risk and BMD change: analysis from the FNIH-ASBMR SABRE project
    Marian Schini, Tatiane Vilaça, Li‐Yung Lui, Susan K. Ewing, Austin R. Thompson, Eric Vittinghoff, Douglas C. Bauer, Mary Bouxsein, Dennis M. Black, Richard Eastell · 2024 · Journal of Bone and Mineral Research
91. Treatment of osteoporosis in postmenopausal hip fracture patients after geriatric rehabilitation
    Markus Gosch, Tobias Roth, Christian Kammerlander, Birgit Joosten-Gstrein, Ursula Benvenuti-Falger, Michael Blauth, Monika Lechleitner · 2011 · Zeitschrift für Gerontologie und Geriatrie
92. Positive Effects of a Sufficient Pre-fracture Serum Vitamin D Level on the Long-Term Survival of Hip Fracture Patients in Finland: A Minimum 11-Year Follow-Up
    Ilona Nurmi-Lüthje, Peter M.J. Lüthje, Juha-Pekka Kaukonen, Matti Kataja · 2015 · Drugs & Aging
93. Pharmacology of Bisphosphonates in Patients with Chronic Kidney Disease
    Susan M. Ott · 2015 · Seminars in Dialysis
94. Bisphosphonate-associated osteonecrosis of the jaw.
    Aliya Aziz Khan · 2008 · Europe PMC (PubMed Central)
95. A comparison of bone density and bone morphology between patients presenting with hip fractures, spinal fractures or a combination of the two
    Richard G. Crilly, Lizebeth Cox · 2013 · BMC Musculoskeletal Disorders
96. Genetic profiling and individualized prognosis of fracture
    Bich N. H. Tran, Nguyen D Nguyen, Vinh X Nguyen, John A. Eisman, Tuan V. Nguyen · 2010 · Journal of Bone and Mineral Research
97. Controlled Delivery of Zoledronate Improved Bone Formation Locally In Vivo
    Wenlong Gou, Xin Wang, Jiang Chen Peng, Qiang Lu, Yu Wang, Yu Wang, Quanyi Guo, Xupeng Gao, Wenjing Xu, Shibi Lu · 2014 · PLoS ONE
98. Mechanistic and therapeutic insights gained from studying rare skeletal diseases
    Laura Lowe Tosi, Matthew L. Warman · 2015 · Bone
99. Women with Cardiovascular Disease Have Increased Risk of Osteoporotic Fracture
    Jian Sheng Chen, Christopher Hogan, Greg Lyubomirsky, Philip N. Sambrook · 2010 · Calcified Tissue International
100. Osteoporosis medication dispensing for older Australian women from 2002 to 2010: influences of publications, guidelines, marketing activities and policy
     Geeske M. E. E. Peeters, Susan E. Tett, Emma L. Duncan, Gita Devi Mishra, Annette Jane Dobson · 2014 · Pharmacoepidemiology and Drug Safety